Back to today’s briefing

Story perspectives

Myriad Genetics Target Price Suggests 60% Stock Surge

1/18/2025

48 4

Summary

Story summary

Myriad Genetics (NASDAQ:MYGN) is currently rated "equal weight" by Stephens, with a promising target price of $20, suggesting a potential 60.90% increase. The stock, trading at $12.43, reflects mixed analyst opinions: three sell, seven hold, and four buy ratings. With institutional investors holding a staggering 99.02% of shares, the company's market cap stands at $1.13 billion.

1 of 1

Story summary

Myriad Genetics (NASDAQ:MYGN) is currently rated "equal weight" by Stephens, with a promising target price of $20, suggesting a potential 60.90% increase. The stock, trading at $12.43, reflects mixed analyst opinions: three sell, seven hold, and four buy ratings. With institutional investors holding a staggering 99.02% of shares, the company's market cap stands at $1.13 billion.